in

Olive Garden-parent Darden is 'more attractive' the longer the pandemic drags, Jim Cramer says

Investors should buy Darden Restaurants due to the uncertain future for the U.S. restaurant industry during the coronavirus pandemic, CNBC’s Jim Cramer said Thursday. 

Shares of the Olive Garden owner soared more than 8% on Thursday, after it reported per-share earnings that outpaced Wall Street expectations. And the “Mad Money” host said he believes the stock has room to go higher because Washington has yet to agree on another round of Covid-19 aid, leaving millions of small businesses across the nation in precarious financial footing. 

“Unfortunately, without some help from Congress, you better believe most independent restaurants will not be able to hold out. I know mine can’t,” said Cramer, who owns Bar San Miguel in Brooklyn, New York.

“[It’s] bad news for the economy, for this wholesale decline of all restaurants, but great news for publicly traded companies with the scale to thrive in this environment. That’s why I think Darden’s stock is still a buy, even after today’s run,” he added. 

Darden, which generates about half of its revenue from Olive Garden, has the balance sheet to be able to outlast the pandemic and all of its related business challenges, such as capacity restrictions on indoor dining and the need to pivot to more digital sales and delivery, Cramer said. 

“We learned today that they can shut down half their tables and still make money — so much money that they actually reinstated the dividend and also repaid a $270 million term loan that would strangle most smaller enterprises,” Cramer said. “These guys are on pace to be able to do almost exactly as well as they did before the pandemic.” 

Darden’s stock is down about 10% so far in 2020, but it has rallied significantly of its coronavirus-induced bottom of $26.15 on March 18. Based on Thursday’s close of $97.31, shares are up about 270% from that bottom. 

“The strength in the stock of Darden, it should terrify you. Darden’s winning because its private competitors can’t cope with the Covid-19 economy,” Cramer said. “We’re headed for a world where, if you want to go out for dinner, you won’t have many options other than some big chains with deep pockets. Olive Garden will be the height of fine dining.” 

With all of the uncertainty around the pandemic and potential government aid for small business, Cramer said it’s hard to apply standard valuation metrics such as a price-to-earnings ratio to Darden. “All I know is the stock deserves to go higher, and the longer the pandemic goes on, the more attractive it gets,” he said. 

Cramer said Darden underscores the duality of the U.S. economy during the health crisis. Millions of Americans have lost their jobs and small businesses have gone under, yet Wall Street has rebounded from its sell-off earlier this year and went on to set a series of fresh record highs.

Although September has been a rough month for stocks, the three major averages posted narrow gains Thursday. The Dow Jones Industrial Average added 52 points, or 0.2%, while the benchmark S&P 500 gained 0.3%. The tech-heavy Nasdaq Composite rose 0.4%. 

“Today we got an early glimpse of what happens if there’s no bailout, no grants for struggling businesses that can’t benefit from low interest rates, and as far as the stock market’s concerned, it’s not that big a deal,” Cramer said. 

“Millions of jobs are on the line but they reside in small businesses, ones that don’t show up in the averages,” he added. “But individual stocks sure do, and the winners on a day like today tell you everything you need to know about the losers in the broader economy.”

Democratic leaders and White House negotiators have been at loggerheads since late July, when many of the key provisions in earlier coronavirus relief bills expired. President Donald Trump took a series of executive actions designed at extending some economic relief, particularly around an unemployment insurance enhancement, but a broad package approved by the legislature has yet to arrive. 

And while Democrats in the House are planning to introduce next week a smaller bill than the one they approved in May, at $2.4 trillion, it is still significantly above the roughly $1.3 trillion price tag that had been supported by Republicans. 

Efforts to pass relief have been complicated by the upcoming presidential election, as well as the recent death of Supreme Court Justice Ruth Bader Ginsburg. 

“I’m not going to hold my breath” that there will be a deal soon, Cramer said. “This rally in Darden today says there’s no compromise to be had. Again, though, you wouldn’t know it by looking at the overall averages because the stock market is mostly insulated from the worst parts of the Covid economy.” 

Source: Business - cnbc.com

Trump to sign executive orders protecting preexisting conditions and seeking a way to prevent surprise medical bills

Sanofi isn't cutting corners in coronavirus vaccine development despite acceleration, CEO says